Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-511X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study ; volume:16 ; number:1 ; day:23 ; month:1 ; year:2017 ; pages:1-12 ; date:12.2017
Lipids in health and disease ; 16, Heft 1 (23.1.2017), 1-12, 12.2017
- Urheber
-
Shah, Parth
- Beteiligte Personen und Organisationen
-
Glueck, Charles J.
Goldenberg, Naila
Min, Sarah
Mahida, Chris
Schlam, Ilana
Rothschild, Matan
Huda, Ali
Wang, Ping
SpringerLink (Online service)
- DOI
-
10.1186/s12944-017-0416-7
- URN
-
urn:nbn:de:1111-201703012890
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shah, Parth
- Glueck, Charles J.
- Goldenberg, Naila
- Min, Sarah
- Mahida, Chris
- Schlam, Ilana
- Rothschild, Matan
- Huda, Ali
- Wang, Ping
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9